Department of Surgery and Cancer, Imperial College London, London, UK.
Breast Unit, Charing Cross Hospital, Imperial College NHS Trust, London, UK.
Ann Surg Oncol. 2024 Jun;31(6):3939-3947. doi: 10.1245/s10434-024-15153-8. Epub 2024 Mar 23.
Ductal carcinoma in situ (DCIS) is associated with risk of positive resection margins following breast-conserving surgery (BCS) and subsequent reoperation. Prior reports grossly underestimate the risk of margin positivity with IBC containing a DCIS component (IBC + DCIS) due to patient-level rather than margin-level analysis.
The aim of this study was to delineate the relative risk of IBC + DCIS compared with pure IBC (without a DCIS component) on margin positivity through detailed margin-level interrogation.
A single institution, retrospective, observational cohort study was conducted in which pathology databases were evaluated to identify patients who underwent BCS over 5 years (2014-2019). Margin-level interrogation included granular detail into the extent, pathological subtype and grade of disease at each resection margin. Predictors of a positive margin were computed using multivariate regression analysis.
Clinicopathological details were examined from 5454 margins from 909 women. The relative risk of a positive margin with IBC + DCIS versus pure IBC was 8.76 (95% confidence interval [CI] 6.64-11.56) applying UK Association of Breast Surgery guidelines, and 8.44 (95% CI 6.57-10.84) applying the Society of Surgical Oncology/American Society for Radiation Oncology guidelines. Independent predictors of margin positivity included younger patient age (0.033, 95% CI 0.006-0.060), lower specimen weight (0.045, 95% CI 0.020-0.069), multifocality (0.256, 95% CI 0.137-0.376), lymphovascular invasion (0.138, 95% CI 0.068-0.208) and comedonecrosis (0.113, 95% CI 0.040-0.185).
Compared with pure IBC, the relative risk of a positive margin with IBC + DCIS is approximately ninefold, significantly higher than prior estimates. This margin-level methodology is believed to represent the impact of DCIS more accurately on margin positivity in IBC.
导管原位癌(DCIS)与保乳手术后(BCS)的阳性切缘以及随后的再次手术有关。由于患者水平而非切缘水平的分析,以前的报告严重低估了包含 DCIS 成分的浸润性乳腺癌(IBC+DCIS)的切缘阳性风险。
本研究旨在通过详细的切缘水平检测,明确 IBC+DCIS 与纯 IBC(无 DCIS 成分)相比,在切缘阳性方面的相对风险。
进行了一项单中心、回顾性、观察性队列研究,对 5 年内(2014-2019 年)的患者进行了 BCS 并对其病理数据库进行了评估。切缘水平的检测包括对每个切缘的疾病范围、病理亚型和分级的详细信息。使用多变量回归分析计算阳性切缘的预测因素。
对 909 名女性的 5454 个切缘的临床病理细节进行了检查。应用英国乳腺外科协会指南时,IBC+DCIS 与纯 IBC 相比,阳性切缘的相对风险为 8.76(95%置信区间[CI]为 6.64-11.56),而应用外科肿瘤协会/美国放射肿瘤学会指南时,该风险为 8.44(95%CI 为 6.57-10.84)。切缘阳性的独立预测因素包括年轻患者年龄(0.033,95%CI 0.006-0.060)、较低的标本重量(0.045,95%CI 0.020-0.069)、多灶性(0.256,95%CI 0.137-0.376)、脉管侵犯(0.138,95%CI 0.068-0.208)和粉刺坏死(0.113,95%CI 0.040-0.185)。
与纯 IBC 相比,IBC+DCIS 的阳性切缘的相对风险约为 9 倍,明显高于以前的估计。这种切缘水平的方法被认为更准确地反映了 DCIS 对 IBC 切缘阳性的影响。